Roivant Sciences Ltd. (NASDAQ:ROIV) Holdings Lessened by Corbin Capital Partners L.P.

Corbin Capital Partners L.P. lowered its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 69.1% in the 4th quarter, HoldingsChannel reports. The fund owned 46,641 shares of the company’s stock after selling 104,245 shares during the period. Roivant Sciences accounts for approximately 0.9% of Corbin Capital Partners L.P.’s holdings, making the stock its 9th largest holding. Corbin Capital Partners L.P.’s holdings in Roivant Sciences were worth $552,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the stock. Nordea Investment Management AB boosted its holdings in shares of Roivant Sciences by 22.5% in the 4th quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock worth $3,306,000 after purchasing an additional 52,031 shares during the period. TOMS Capital Investment Management LP bought a new stake in Roivant Sciences in the third quarter worth $46,333,000. Barclays PLC boosted its stake in Roivant Sciences by 19.7% during the third quarter. Barclays PLC now owns 459,521 shares of the company’s stock worth $5,302,000 after buying an additional 75,609 shares during the period. Loomis Sayles & Co. L P increased its position in Roivant Sciences by 13.3% during the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock valued at $45,147,000 after acquiring an additional 458,601 shares during the last quarter. Finally, Retirement Systems of Alabama increased its position in Roivant Sciences by 26.9% during the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after acquiring an additional 112,286 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the sale, the chief accounting officer now directly owns 163,264 shares in the company, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CIO Mayukh Sukhatme sold 185,946 shares of the stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $12.00, for a total value of $2,231,352.00. Following the transaction, the executive now directly owns 18,836,547 shares in the company, valued at $226,038,564. The trade was a 0.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,875,586 shares of company stock valued at $21,491,661 over the last quarter. 7.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Roivant Sciences currently has a consensus rating of “Buy” and an average price target of $18.08.

Roivant Sciences Trading Up 0.3 %

NASDAQ ROIV opened at $10.97 on Friday. The stock has a market cap of $7.83 billion, a PE ratio of -73.13 and a beta of 1.26. Roivant Sciences Ltd. has a 12 month low of $9.93 and a 12 month high of $13.06. The company’s 50-day moving average price is $10.78 and its 200-day moving average price is $11.48.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, sell-side analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.